Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 634 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR SABCS 2021: New Research and Updates in Breast Cancer Treatment and... January 20, 2022 Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context May 22, 2026 Record Impact Factor for Annals of Oncology Highlights Growing Influence of... July 2, 2026 How to Cope With Panic Attacks During Cancer July 12, 2022 Load more HOT NEWS How TRACERx is helping us predict lung cancer’s next move Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in...
